Alnylam Stock Based Compensation from 2010 to 2025

ALNY Stock

USD 268.46 2.56 0.94%

Alnylam Pharmaceuticals Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2004-12-31

Previous Quarter

45.8 M

Current Value

91.6 M

Quarterly Volatility

25.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.5 M, Interest Expense of 149 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 12.79, Dividend Yield of 0.0 or PTB Ratio of 474. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Alnylam Pharmaceuticals over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Alnylam Pharmaceuticals' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Alnylam Stock Based Compensation Regression Statistics

	Arithmetic Mean	121,840,012
	Geometric Mean	71,587,902
	Coefficient Of Variation	79.67
	Mean Deviation	84,195,512
	Median	139,873,000
	Standard Deviation	97,070,274
	Sample Variance	9422.6T
	Range	281.6M
	R-Value	0.97
	Mean Square Error	528.8T
	R-Squared	0.95
	Slope	19,847,684
	Total Sum of Squares	141339.6T

Alnylam Stock Based Compensation History

	2025	285.7 M
	2024	272.1 M
	2023	221.7 M
	2022	230.6 M
	2021	165.7 M
	2020	139.9 M
	2019	174.8 M

Other Fundumenentals of Alnylam Pharmaceuticals

Stock Based Compensation To Revenue

Alnylam Pharmaceuticals Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Intangible Assets	Net Receivables	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.15	0.39	-0.98	0.89	0.97	0.93	0.99	0.96	0.26	0.88	0.33	0.85	0.89	0.83	-0.25	0.99	-0.63	-0.6	0.82	-0.85	-0.89	0.57	0.94
Total Stockholder Equity	-0.15		-0.63	0.29	-0.15	-0.15	-0.49	-0.13	-0.19	0.33	-0.55	0.18	-0.39	-0.5	0.19	0.99	-0.08	-0.45	0.14	-0.63	-0.1	0.39	-0.61	-0.46
Net Debt	0.39	-0.63		-0.52	0.32	0.48	0.57	0.35	0.46	0.09	0.58	0.23	0.47	0.48	0.29	-0.59	0.36	0.09	-0.42	0.52	-0.35	-0.63	0.45	0.54
Retained Earnings	-0.98	0.29	-0.52		-0.91	-0.96	-0.96	-0.96	-0.98	-0.18	-0.94	-0.36	-0.89	-0.92	-0.81	0.38	-0.97	0.55	0.64	-0.88	0.85	0.95	-0.58	-0.96
Accounts Payable	0.89	-0.15	0.32	-0.91		0.87	0.84	0.88	0.92	0.1	0.84	0.32	0.76	0.8	0.78	-0.25	0.93	-0.6	-0.51	0.77	-0.79	-0.85	0.42	0.84
Short Term Investments	0.97	-0.15	0.48	-0.96	0.87		0.91	0.95	0.97	0.3	0.85	0.35	0.84	0.86	0.8	-0.24	0.97	-0.55	-0.71	0.78	-0.91	-0.87	0.54	0.91
Total Liab	0.93	-0.49	0.57	-0.96	0.84	0.91		0.92	0.91	0.11	0.97	0.22	0.89	0.96	0.66	-0.58	0.89	-0.39	-0.58	0.95	-0.72	-0.93	0.72	0.99
Total Current Assets	0.99	-0.13	0.35	-0.96	0.88	0.95	0.92		0.93	0.19	0.89	0.29	0.85	0.9	0.82	-0.24	0.97	-0.66	-0.56	0.84	-0.83	-0.86	0.6	0.92
Property Plant Equipment	0.96	-0.19	0.46	-0.98	0.92	0.97	0.91	0.93		0.3	0.86	0.46	0.87	0.85	0.8	-0.28	0.98	-0.53	-0.72	0.8	-0.91	-0.93	0.44	0.93
Current Deferred Revenue	0.26	0.33	0.09	-0.18	0.1	0.3	0.11	0.19	0.3		-0.04	0.62	0.01	-0.06	0.38	0.33	0.25	-0.21	-0.27	-0.11	-0.32	-0.12	-0.03	0.19
Long Term Debt	0.88	-0.55	0.58	-0.94	0.84	0.85	0.97	0.89	0.86	-0.04		0.21	0.87	0.96	0.62	-0.63	0.85	-0.36	-0.51	0.98	-0.65	-0.9	0.75	0.96
Short Term Debt	0.33	0.18	0.23	-0.36	0.32	0.35	0.22	0.29	0.46	0.62	0.21		0.27	0.13	0.43	0.16	0.4	-0.27	-0.44	0.13	-0.49	-0.37	-0.13	0.32
Intangible Assets	0.85	-0.39	0.47	-0.89	0.76	0.84	0.89	0.85	0.87	0.01	0.87	0.27		0.94	0.57	-0.49	0.85	-0.37	-0.59	0.87	-0.71	-0.86	0.49	0.91
Net Receivables	0.89	-0.5	0.48	-0.92	0.8	0.86	0.96	0.9	0.85	-0.06	0.96	0.13	0.94		0.57	-0.6	0.85	-0.38	-0.5	0.97	-0.65	-0.85	0.72	0.95
Common Stock	0.83	0.19	0.29	-0.81	0.78	0.8	0.66	0.82	0.8	0.38	0.62	0.43	0.57	0.57		0.11	0.85	-0.81	-0.47	0.51	-0.81	-0.73	0.31	0.66
Net Tangible Assets	-0.25	0.99	-0.59	0.38	-0.25	-0.24	-0.58	-0.24	-0.28	0.33	-0.63	0.16	-0.49	-0.6	0.11		-0.18	-0.35	0.17	-0.71	-0.02	0.46	-0.65	-0.55
Capital Surpluse	0.99	-0.08	0.36	-0.97	0.93	0.97	0.89	0.97	0.98	0.25	0.85	0.4	0.85	0.85	0.85	-0.18		-0.64	-0.65	0.78	-0.9	-0.9	0.45	0.91
Deferred Long Term Liab	-0.63	-0.45	0.09	0.55	-0.6	-0.55	-0.39	-0.66	-0.53	-0.21	-0.36	-0.27	-0.37	-0.38	-0.81	-0.35	-0.64		0.12	-0.28	0.56	0.42	-0.12	-0.38
Long Term Investments	-0.6	0.14	-0.42	0.64	-0.51	-0.71	-0.58	-0.56	-0.72	-0.27	-0.51	-0.44	-0.59	-0.5	-0.47	0.17	-0.65	0.12		-0.45	0.85	0.68	-0.15	-0.6
Long Term Debt Total	0.82	-0.63	0.52	-0.88	0.77	0.78	0.95	0.84	0.8	-0.11	0.98	0.13	0.87	0.97	0.51	-0.71	0.78	-0.28	-0.45		-0.55	-0.84	0.78	0.94
Short Long Term Debt	-0.85	-0.1	-0.35	0.85	-0.79	-0.91	-0.72	-0.83	-0.91	-0.32	-0.65	-0.49	-0.71	-0.65	-0.81	-0.02	-0.9	0.56	0.85	-0.55		0.81	-0.21	-0.73
Net Invested Capital	-0.89	0.39	-0.63	0.95	-0.85	-0.87	-0.93	-0.86	-0.93	-0.12	-0.9	-0.37	-0.86	-0.85	-0.73	0.46	-0.9	0.42	0.68	-0.84	0.81		-0.46	-0.92
Net Working Capital	0.57	-0.61	0.45	-0.58	0.42	0.54	0.72	0.6	0.44	-0.03	0.75	-0.13	0.49	0.72	0.31	-0.65	0.45	-0.12	-0.15	0.78	-0.21	-0.46		0.69
Capital Stock	0.94	-0.46	0.54	-0.96	0.84	0.91	0.99	0.92	0.93	0.19	0.96	0.32	0.91	0.95	0.66	-0.55	0.91	-0.38	-0.6	0.94	-0.73	-0.92	0.69

Click cells to compare fundamentals

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	272.1 M	285.7 M
Stock Based Compensation To Revenue	0.12	0.11

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Stock Based Compensation from 2010 to 2025

Latest Alnylam Pharmaceuticals' Stock Based Compensation Growth Pattern

Alnylam Stock Based Compensation Regression Statistics

Alnylam Stock Based Compensation History

Other Fundumenentals of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Based Compensation component correlations

About Alnylam Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Alnylam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY